BLUEMATRIX
24.7.2024 10:01:29 CEST | Business Wire | Press release
BlueMatrix, the world’s largest publisher of investment research, has announced that, since the start of 2024 and a strategic growth investment by leading software investment firm’s Thoma Bravo, new revenue has grown an impressive 74% on the same period last year. BlueMatrix is doubling down on its investment in its clients through a growth strategy that includes strengthening its leadership team with two major C-suite appointments. Its new Chief Financial Officer and Chief Revenue Officer have over 40 years of combined experience in scaling software companies within the financial services landscape.
Joining BlueMatrix’s leadership team, overseen by Chief Executive Officer and President Patricia Horotan and alongside Chief Operating Officer Mirko Consolascio, is Ben McFadden, appointed as Chief Financial Officer. He brings more than 15 years of enterprise software strategic finance expertise. He was previously Head of Finance at Nintex, a leader in global automation software, and Revalize, a quote-to-cash provider for manufacturing. His prior experience includes five years as a sell-side equity research analyst at Keybanc Capital Markets focused on infrastructure software.
Ben McFadden commented: “I witnessed BlueMatrix’s trajectory firsthand seven years ago as a sell-side equity analyst and now I get to be a part of this exceptional team. My focus is on maintaining our impressive 97% customer retention, enabled by our international expertise, industry-leading products, and outstanding service. With Thoma Bravo's strategic investment too, I believe the future for BlueMatrix is very bright indeed.”
Also joining BlueMatrix’s leadership team is Bryan North-Clauss, appointed as its Chief Revenue Officer. Most recently, he held the position of Chief Revenue Officer at Truv, after leading AlphaSense's financial services sales division, where he contributed to growing its annual recurring revenue by 350% and productivity per salesperson by 400%. Earlier in his career, Bryan held senior roles in fixed income sales at Deutsche Bank, Morgan Stanley, Citi, and Lehman Brothers. His career began as a founding member of software firm JobDirect.com, acquired by Korn/Ferry.
Bryan North-Clauss stated: “This is a pivotal moment for me to join BlueMatrix and contribute to its ambitious expansion plans following January’s strategic investment by Thoma Bravo. Six months in, my focus remains on reinforcing our market dominance and share in our core verticals. For instance, 75% of all sell-side research is published using the BlueMatrix platform, highlighting our strong product-market fit and commitment to delivering world-class service. Moving forward, we aim to invest further in our clients' success to drive future growth.”
BlueMatrix’s continued growth strategy will focus on moving to new markets, including Europe, APAC region, and South America, to deliver technical expertise and client experience to a new audience of global clients. There will also be increased focus on enhancing the innovation that optimises workflows, scalability, and deep integration across its entire product suite to meet the evolving needs of its worldwide client base.
Patricia Horotan, Chief Executive Officer and President of BlueMatrix, said: “Our plans to expand our platform and portfolio of products for existing and new clients alike will not only reinforce our world-leading status, but bring the most advanced investment solutions to new generations of investors. Working with my leadership team, and in partnership with Thoma Bravo, we are excited to take BlueMatrix to new markets and new audiences.”
Founded in 1999, BlueMatrix employs 147 people, with 42% in the US and 39% in Romania. Expansion into new markets, including Europe, APAC region, and South America, is planned for the second half of this year, highlighting the company's international growth.
BlueMatrix offers fully integrated, cloud-based solutions for the entire investment research production workflow, including content creation, compliance approval, distribution, hosting, and analytics. This comprehensive suite positions BlueMatrix as the only global platform covering the complete investment research lifecycle.
About BlueMatrix
BlueMatrix, the world’s largest publisher of investment research, is a pioneering SaaS provider connecting content publishers and readers. Since 1999, BlueMatrix has developed advanced research-creation and distribution software for the financial services sell side, serving over 800 banks and institutions worldwide and supporting the production and publishing of 1.4 million items annually.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724453243/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom